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KESAN EKSTRAK CHANNA STRIATUS BERBANDING DENGAN 
GLUKOSAMINA SULFAT KE ATAS PENANDA RAWAN DAN PENANDA-




Osteoarthritis lutut (KOA) adalah sejenis osteoarthritis yang biasa didapati. 
Rawatan yang sedia ada hanya melegakan kesakitan kepada pesakit osteoarthritis. Kesan 
sampingan pada rawatan sekarang menggalakkan lebih banyak kajian dijalankan untuk 
menghasilkan produk semulajadi yang mempunyai kurang kesan sampingan. Channa 
striatus (CS) adalah ikan air tawar yang merupakan remedi semulajadi dikalangan 
masyarakat setempat yang dapat merawat pelbagai penyakit tanpa bukti sainstifik. 
Objektif kajian ini adalah untuk menilai dan membandingkan kesan pengambilan ekstrak 
CS dalam dua dos (1000 mg/hari dan 500 mg/hari) berlainan secara oral ke atas penanda-
penanda rawan (COMP) dan keradangan (COMP, COX-2 dan PGE2) di kalangan pesakit 
KOA. Seramai seratus empat puluh lapan pesakit mengambil bahagian di dalam kajian 
rawak, ujian buta dwipihak dan percubaan kawalan plasebo dengan membandingkan 
kesan dua dos ekstrak CS yang berlainan dengan glukosamina sulfate (GS) berbanding 
dengan kumpulan plasebo. Sampel darah diambil dalam tempoh masa berlainan (baseline 
dan 6 bulan) dan tahap COMP, COX-2 dan PGE2 dinilai dengan menggunakan kit yang 
terdapat di pasaran dan keputusan p<0.05 dianggap signifikan secara statistik. 
Pengurangan tahap COX-2 secara signifikan boleh dilihat pada kedua-dua kumpulan 
ekstrak pada dos yang berbeza serta kumpulan GS dengan berbanding pada kumpulan 
plasebo. Pengurangan tahap COMP pada kedua-dua kumpulan dos ekstrak CS memberi 
xii 
 
gambaran bahawa ekstrak CS memiliki kesan perlindungan rawan kepada pesakit KOA. 
Walaubagaimanapun, tiada pengurangan tahap PGE2 yang signifikan dapat dilihat pada 
kajian ini. Perbandingan di antara kumpulan CS 1000 mg/hari dan CS 500 mg/hari 
menunjukkan pengurangan tahap COX-2 yang significant. Kesimpulannya, penggunaan 
ekstrak CS secara oral mempunyai potensi dalam perawatan pesakit KOA. Namun begitu, 
























THE EFFECTS OF CHANNA STRIATUS COMPARED WITH GLUCOSAMINE 
SULPHATE IN SERUM CARTILAGE AND INFLAMMATORY MARKERS IN 
KNEE OSTEOARTHRITIS PATIENTS 
 
ABSTRACT 
Knee osteoarthritis (KOA) is one of the commonest types of osteoarthritis (OA). 
Currently, the treatment is to provide the pain relief to OA patients. The concern for the 
side effects of current treatment encouraged the studies to search for natural products to 
reduce the side effects. Channa striatus (CS) is a freshwater fish that proclaimed as natural 
remedies to various illnesses by local communities without scientific evidence. Therefore, 
the objective of this study was to evaluate the effect of oral administration of different 
doses of CS extract (1000 mg/day and 500 mg/day) on the level of cartilage marker, 
Cartilage Oligomeric Protein (COMP) and inflammatory markers, Cyclooxgenase-2 
(COX-2) and Prostaglandin E2 (PGE2) and compared within Glucosamine Sulphate (GS) 
treatment in KOA patients. One hundred and forty-eight patients were enrolled in this 
randomized, double-blind, placebo-controlled trial comparing the effect of two doses of 
oral CS extract (1000 mg/day and 500 mg/day) and glucosamine sulphate (GS) with the 
placebo group. Blood samples were collected at different-time period (baseline and six 
months) to assess the level of COMP, COX-2 and PGE2 using commercially available kits 
and the result with p<0.05 considered as statistically significant. There was a significant 
reduction of COX-2 level in both doses of the CS extract groups and GS group compared 
to the placebo group patients. Reduction of COMP level in both doses of CS extract groups 
might suggest the chondroprotective effect of CS extract on KOA patients. However, there 
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was no significant difference found in the PGE2 level. Comparison between CS 
1000mg/day and CS 500 mg/day groups with GS group showed a significant reduction in 
COX-2 level. In conclusion, orally administrated CS extract can serve as potential 
candidate in the treatment of KOA patients. However, further studies required to 

















Knee osteoarthritis (KOA) is the leading causes of disability in elderly population 
globally (Neogi, 2013, French et al., 2016). The leading cause of disability and pain in 
elderly population is characterized by degradation of articular cartilage. The fundamental 
reason causing KOA is that the normal mechanism of cartilage production is disrupted 
and there is no equilibrium between catabolism and anabolism of cartilage production. 
Erosion of articular cartilage causes pain and disability, hence reduces the quality of life. 
The pathophysiology of KOA is about the interaction of mechanical, cellular and 
biochemical processes. Cartilage is composed of water, collagen and proteoglycans. In 
healthy cartilage, remodeling occurs when there is degradation of cartilage and it is 
replaced by chondrocytes. Chondrocytes will form a new articular cartilage. However, in 
KOA, this process is disrupted. The disruption of the remodeling process leads to cartilage 
damage, joint spaces narrowing and with time subchondral cysts and osteophytes 
formation.  
Biochemically, inflammation had been associated with KOA (Mathiessen and 
Conaghan, 2017; Haywood et al., 2003). It is an element of natural response from host 
towards injury and infection. In early stage of KOA, synovitis occurs (Benito et al., 2005, 
Atukorala et al., 2016). Synovitis is inflammation of synovial lining of the joint. Signs 
such as swelling of the joint associated with joint pain and stiffness in KOA patients 
indicate local inflammation (Pelletier et al., 2001, Scanzello and Loeser, 2015) and it has 
been widely acceptable as part of KOA (Myers et al., 1990, Ene et al., 2015). Synovitis is 
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representing the production of various inflammatory cytokines (tissue necrosis factor-α 
[TNF-α], Interleukin-1β [IL-1β], Interleukin-6 [IL-6] and Interleukin-8 [IL-8]), 
inflammatory biomarkers (prostaglandins [PGs] and cyclooxygenase-2 [COX-2]) 
(Sokolove and Lepus, 2013, Wojdasiewicz et al., 2014). Over the years, researchers have 
made tremendous effort in trying to recognize inflammatory biomarkers related to KOA 
which can be detected even before radiographic changes taking place. The commonly 
studied inflammatory markers were COX-2 and Prostaglandin E2 (PGE2) (Fan et al., 2015, 
Guler et al., 2011, Pecchi et al., 2012, Zuo et al., 2011) and lately some studies were using 
serum biomarker such as cartilage oligomeric protein (COMP), matrix metalloproteinase-
3, type II collagen degradation and interleukin-16 (IL-16) to assess the degree of cartilage 
destruction in joints (Georgiev et al., 2018, Das Gupta et al., 2017, Arellano et al., 2017). 
COMP is a tissue-specific protein that binds to type II collagen fibers network of 
articular cartilage and it belongs to thrombospondin family. It is synthesized by synovial 
cells and chondrocytes with the activation of proinflammatory cytokines. Majority of 
COMP found in the joint is derived from articular cartilage. COMP molecules are 
important for maintaining the properties and integrity of the collagen network. It 
contributes to the material properties of biological tissues (Chen et al., 2005, Rosenberg 
et al., 1998, Luo et al., 2017). It also binds to aggrecan which is the major proteoglycan 
in articular cartilage. Aggrecan provides a hydrated gel structure that presents the cartilage 
with load bearing ability by hyaluronan and link protein interaction (Kiani et al., 2002, 
Roughley and Mort, 2014). The breakdown of the cartilage, releases COMP first into 
synovial fluid followed by into the bloodstream (Wislowska and Jablonska, 2005). The 
higher level of serum COMP detected indicates the severity of cartilage destruction 
(Larsson et al., 2002). 
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Another biomarker of interest in KOA is COX-2. COX-2 is multifunctional 
enzyme that catalyzes conversion of arachidonic acid (AA) to Prostaglandin H2 (PGH2) in 
inflammatory pathway. It is metabolized by Prostaglandin E synthase (PGES) into the end 
product which is PGE2.  (Martel-Pelletier et al., 2003, Wojdasiewicz et al., 2014). The 
highest levels of COX-2 are found mainly in the brain, vas deferens and renal cortex 
(Guilak et al., 2004). COX-2 expression is increased during inflammation and other 
pathologic situations. Its expression is highly elevated by tumour promoters, pro-
inflammatory agents, growth factors, mitogens and oncogenesis. In normal physiological 
conditions, COX-2 often found low in blood. However, it plays an important role in 
articular cartilage disease and it facilitates the inflammatory cytokine-induced metabolic 
imbalance of cartilage proteoglycans (Maldonado and Nam, 2013). 
PGE2 is the end product of arachidonic acid (AA) which has been studied and 
associated with KOA. PGE2 is the most abundant eicosanoid and a potent lipid mediator. 
There are four principle bioactive PGs generated in vivo: PGE2, Prostacyclin (PGI2), 
Prostaglandin D2 (PGD2) and Prostaglandin F2α (PGF2α). PGE2 is regulated by COX-2 and 
PGES. It is involved in many physiological conditions such as regulation of immune 
responses, blood pressure, gastrointestinal integrity and fertility. Secreted PGE2 acts in an 
autocrine or paracrine manner through its four G protein coupled receptors which are EP1, 
EP2, EP3 and EP4. PGE2 is known as the major prostaglandin synthesized by cartilage in 
KOA. The amounts of PGE2 in KOA potential to increase to 50-fold higher than in normal 
cartilage (Amin et al., 1997, Cho et al., 2015). 
Up to date, there is still no curative treatment for KOA. Currently KOA is being 
treated symptomatically with drugs such as nonsteroidal anti-inflammatory drugs 
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(NSAIDs) and glucosamine (GlcN). Glucosamine provide modest pain relief in patients 
with KOA. Glucosamine (2-amino-2-deoxy-D-glucose) is a monosaccharide and 
produced naturally in the body and it is an essential part of proteoglycans, 
glycosaminoglycans and collagen (Jerosch, 2011). In United States, GlcN is used by five 
million people annually and consumed as a dietary supplement to promote joint health 
(Stumpf and Lin, 2006, Kennedy, 2005). Generally, GlcN is absorbed rapidly and in 
constant state. Under in vivo condition, GlcN can be synthesized from glucose and is used 
to produce glycosaminoglycan chains from which proteoglycans are formed (Huskisson, 
2008). In KOA, GlcN was reported to have the ability as chondroprotective and anti-
inflammatory agent thus have the possibility to reduce the symptoms in KOA (Lomonte 
et al., 2018; Naraoka et al.,2017; Li et al., 2018; Veronesi et al., 2017; Richy et al., 2003). 
Alternative therapies used for the treatment of KOA include herbal supplements, 
acupuncture and electromagnets (Rodriguez-Merchan, 2016; Garland et al., 2007). 
Nowadays, there is an interest towards natural remedies for KOA. Channa striatus (CS) 
also known as Haruan in Malaysia has been considered as a natural remedy for KOA. It 
has good nutritive value and easily available. It is enriched with many amino acids such 
as glycine, lysine, aspartic acid, proline, glutamic acid and fatty acids such as palmitic 
acid, docosahexanoic acid (DHA) and eicosapentaenoic acid (EPA) (Dahlan et. al., 2010; 
Mat Jais et. al., 1998; Zakaria et. al., 2007; Zuraini et. al., 2006). The amino acids and 
fatty acids contained in CS is known to promote in wound healing in caesarean delivery 
and improve the wound healing texture (Baie and Sheikh, 2000b, Baie and Sheikh, 2000a, 
Ab Wahab et al., 2015). The fatty acids such as DHA and EPA are capable in reducing 
the levels of pro-inflammatory mediators (Al-Saffar et al., 2011a; Al-Saffar et al., 2011b; 
5 
 
Michelle et al., 2004). Many studies reported the therapeutic potentials of CS as anti-
microbial, anti-depressant, neuro regenerative and anti-inflammatory agent. (Abedi et. al., 
2012; Mat Jais et. al., 1997; Saleem et. al., 2011; Wei et. al., 2010). It is also popular in 
traditional medicine to promote wound healing. Given the possible anti-inflammatory 
property of CS in treating diseases with an inflammatory component, the amelioration of 
KOA and its mechanism on how it works as an anti-inflammatory agent is still not clear. 
This study is done to compare the serum levels of cartilage biomarker (COMP) 
and inflammatory biomarkers (COX-2 and PGE2) on KOA patients consuming oral CS 
and glucosamine sulphate (GS). This study also aims to compare the serum levels of 
cartilage and inflammatory markers (COMP, COX-2 and PGE2) at different doses of CS 
extract (1000 mg/day or 500 mg/day) given to KOA patients. With the understanding of 
CS acting on KOA could generate further ideas on the use of natural remedies as an 
alternative in the treatment of KOA. 
 
1.1 Justification of the study 
 
 
KOA is a major issue globally. Current treatment for KOA is orally administered 
GlcN and NSAIDs. But many side effects found on treatment with NSAIDs and thus the 
current focus is by treatment with natural products on KOA (Hammad et al., 2015; 
Campbell et al., 2015; Jo et al., 2017). In this study, CS extract chosen as it possesses 
many anti-inflammatory and many beneficial properties. It is also been shown to have a 
protective effect on wound healing on post Lower Segment Caesarean Section (LSCS) 
(Ab Wahab et al., 2015). But there is no clinical trial been done on the effect of CS on 
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KOA patients. GS is used as a positive control in this study since it is a gold standard for 
the treatment of KOA. Therefore, to our knowledge this is the first study to assess and 
compare the effectiveness of GlcN and CS extracts on cartilage and inflammatory 
biomarkers on KOA. 
1.2 General objective: 
 
To assess and compare the effect of oral administration of different doses of CS 
extract versus GS on the level of cartilage and inflammatory biomarkers in KOA 
patients. 
 
1.3 The Specific Objectives: 
 
a. To assess and compare the levels of inflammatory biomarkers (COX-2 and 
PGE2) among CS extract (1000 mg/day and 500 mg/day), GS and placebo 
administered groups of KOA patients. 
b. To assess and compare the level of cartilage biomarker, COMP among CS 
extract (1000 mg/day and 500 mg/day) and GS and placebo administered 
groups of KOA patients. 
c. To compare the levels of inflammatory biomarkers (COX-2 and PGE2) and 
COMP within the CS extract (1000 mg/day and 500 mg/day) administered 






1.4 Benefit of the study 
 
  Since the side effect and cost of GlcN are increasing, this study will provide 
scientific evidence on the comparison of cartilage and inflammatory biomarkers 
level in KOA patients consuming CS extract or GS where CS can have less side 
effect and cost-effective. Administration of NSAIDs as the first line of KOA 
treatment is mainly to reduce the inflammation in KOA joint and the properties in 
CS extract can aid in reducing the inflammation thus slow down the KOA 
progression.  
 
1.5 Research hypothesis 
 
  CS extract provides a significant improvement on articular cartilage of 
KOA patients with the decreased level of serum COMP, COX-2 and PGE2 when 














CHAPTER 2  
LITERATURE REVIEW 
 
2.1. Epidemiology of Osteoarthritis (OA) 
 
Osteoarthritis (OA) is one of the important causes of chronic disability in old age 
and is the commonest form of arthritis and joint disorder. OA usually affects the 
movements on the spine, knee, hip hands and any other smaller joints. Knee Osteoarthritis 
(KOA) responsible for 83% of OA anxiety. Projection about 10-15% adult age more than 
60 years old is affected by OA worldwide. Estimation of more than 20% population will 
be affected by OA and more than 40 million people will be critically disabled by the year 
2050 (Who.int, 2019). In the USA, two-thirds of adults aged between 45 and 65 years old 
represented two millions cases of symptomatic KOA (Deshpande et al., 2016).  Studies 
indicated that females were more susceptible to KOA (4.5% male and 19% female) in 
Korea (Park et al., 2017) and (5% men and 11.3% female) in Japan (Muraki et al., 2010). 
There is roughly 3.6% of world population (250 million people) is affected by KOA (Vos 
et al., 2012). Prevalence of KOA is accountable to 6% of the global population with 
estimation of 67 million population in the USA and 100 million people in China by 2020 
(Zhang and Jordan, 2008). A retrospective study conducted by Wallace et al. dated back 
to prehistoric until postindustrial era indicated that the prevalence of KOA has doubled 





2.2 Characteristics of Knee Osteoarthritis (KOA) 
 
The prominent characteristics of KOA are the degeneration of articular cartilage 
and formation of reactive new bones. Stiffness, pain and inflammation are the 
characteristics of the affected joints. This indirectly restricts joint movements and reduces 
quality of life to the patients. Further destruction of articular cartilage can cause damage 
to subchondral bone and leads to subchondral bone hardness which diminish stress 
absorption ability and integrity of cartilage (Falah et al., 2010).  
 
2.3 Pathophysiology of KOA 
 
The pathophysiology of the disease is complex and multifactorial. Generally, KOA 
joints are characterized by cartilage degeneration and subchondral bone stiffening. 
Degeneration of cartilage in KOA joints happened when remodeling of cartilage is slower 
than cartilage degeneration. In some worst condition, erosion of cartilage takes place. 
Stiffness of subchondral bone reduces the absorption ability of the bone and causing extra 











(Adapted from Jérémie Sellam and Francis Berenbaum, 2010) 
Figure 2.1: Pathophysiology of KOA 
 
Everyday activities induced the cyclic loading to produce mechanical stress and 
deformation of joints. This process makes the chondrocytes at articular cartilage becomes 
vulnerable to tensile force, fluid flows, osmotic pressure and compressive force (Guilak 
et al., 1999, Bleuel et al., 2015). Pathophysiology of KOA started with microfracture, 
trauma or inflammation by increasing the enzymatic activity and forming “wear” particles 
(Figure 2.1). The “wear” particles are engulfed by macrophages particularly from synovial 
cells sited at synovial membrane. The failure to eliminate the overproduction of “wear” 
particles causes development of inflammatory mediators and decrease in the level of 
growth factor like transforming growth factor beta (TGF-β)(Park et al., 2013, Sokolove 
and Lepus, 2013). This further trigger the chondrocytes to release various types of 
degradative enzymes such as collagenases, aggrecanases, stromelysins and gelatinases. 
The degradative enzymes proceed further to disintegrate collagen and proteoglycan 
structures in articular cartilage. The fragments are actively taken up by macrophages again 
and in turn causes the release of pro-inflammatory cytokines such as TNF-α, IL-1 and  
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IL-6. Cytokine such as IL-1 is known to activate the AA pathway and induces the 
phospholipase A2 (PLA2) which subsequently elevates the cyclooxygenase-2 (COX-2) 
and prostaglandin E2 (PGE2) level (Gilman et al., 1987, Angel et al., 1993). The cytokines 
promptly bind to chondrocytes receptors causing further inhibition of type II collagen 
production and release of matrix metalloproteinases (MMPs) (Stannus et al., 2010). These 
serials which further worsen the condition of events provoked the disturbance of 
homeostasis leading to chondrocytes apoptosis and development of KOA. 
 Basically, there are two types of KOA, primary KOA and secondary KOA. 
Primary KOA is common in elderly population as the wear and tear of the articular 
cartilage caused by aging. Secondary KOA is a type of KOA with specific cause, such as 
injuries, obesity, inactivity, genetics or other diseases. Kellgren & Lawrence (K-L) staging 
system based on radiological examination is widely used by researchers worldwide. There 
are divided into four types of grading, Grade I, Grade II, Grade III and Grade IV 
(Appendix I). Increment in each grades indicating the severity of KOA progression 
respectively (Kellgren and Lawrence, 1957, Felson et al., 2011)  
 
2.4 Risk factors of KOA 
 
Risk factors of KOA can vary from metabolic disorders to physical activities. 
Zhang and Jordan divided the risk factors of KOA into two types: Systemic risk factors 
and local risk factors. Systemic risk factors include age, gender and hormones, races or 
ethnicity, genetics, congenital or development conditions and diet. On the other hand, 
obesity, injury or surgery, occupations, physical activity or sports, mechanical factors and 
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alignment are considered as local risk factors (Zhang and Jordan, 2008). Verbeek and 
colleagues reviewed the studies related to occupational activities leading to KOA. They 
concluded that longer time exposure of squatting and kneeling at work can expose workers 
to KOA (Verbeek et al., 2017). It has also been identified the role of occupational activity 
and sporting with the development of KOA (Shelton et. al., 2016).  
Until today there are no cure for KOA. The main treatment and intervention 
offered are to relief pain and provide better quality of life. Many studies began to explore 
the possibility of KOA related to genetic coding. Recent study managed to identify KOA 
risk loci and efforts of mapping KOA susceptible loci were granted (Loughlin, 2015). It 
is important to have the overall mapping of the genetic architecture of KOA currently it is 
intensively explored by geneticists to prevent and possibly to cure KOA (Zengini et al., 
2018).  
 
2.5 Assessment of KOA  
 
Assessment of KOA consists of few elements: physical examination, plain 
radiography and laboratory testing of biochemical markers. Physical examination 
normally performed when there were complaints of pain at any joints along with patients’ 
demographics and medical history. Plain radiography is an economical and confirmation 
tool to the integrity of the joints especially the knees. At least two planes anterior-posterior 
(A-P) and lateral X-ray films needed to assess the infected joints. The results from X-ray 
were rated with K-L staging system (Kellgren and Lawrence, 1957, Felson et al., 2011).  
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 Lab testing of biochemical markers can aid in diagnosis of KOA along with 
radiography finding. Plasma, serum, urine and synovial fluid are common specimens 
deployed to detect the biomarkers related to KOA. Burden of disease, investigative, 
prognostic, efficacy of intervention and diagnostic (BIPED) are the five categories of 
markers used as the framework for the investigation of KOA biomarker studies (Bauer et 
al., 2006). van Spil et al. did a reviewed for 54 types of biomarkers for knee and hip OA 
by applying BIPED criteria. These included serum COMP, urine collagen type II 
(uCTXII) and serum hyaluronic acid (HA) among others. The finding was serum COMP 
considered to have the best performance compared to all biomarkers available in market. 
It was investigated frequently, widely and had higher scores in most of BIPED categories 
(van Spil et al., 2010). Sudhir Singh et al. reported COMP is more sensitive, specific and 
accurate compared to HA as KOA biomarker (Singh et al., 2015). They concluded COMP 
is a therapeutic and prognostic indicator of KOA and it provides quantitative commentary 
about the success fullness of ongoing treatment (Singh et. al., 2014). 
 Now more researches have ventured into the genetic linkage analysis to investigate 
the possible genes involved in KOA. Ethnic differences in radiographic KOA and level of 
biomarkers of KOA offer an interesting insight that genetic factors is one of the factor 
related to KOA (Clark et al., 1999, Holderbaum et al., 1999). Fifty percent of OA cases 
in the hips, hands and knees were genetically related (Spector et al., 1996). The discovery 
of Type II collagen (COL2A1) provides the path for further work on genetic to discover 
more OA-related genes. 
 Other biomarkers such as COX-2, PGE2 and HA are well known for determining 
the degree of inflammation and destruction in the joints (Willoughby et al., 2000, Lee et 
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al., 2015, Cole et al., 2017). C-terminal cross-linking telopeptide of type I collagen (CTX-
1) and osteocalcin are important to evaluate the condition of bone metabolism in OA (Bai 
and Li, 2016, Cantatore et al., 2004). There are many more biomarkers undiscovered in 
our currently available technology. Early detection via laboratory testing is a major 
challenge to discover a novel biomarker which can detect KOA in the early stage before 
the disease even starts to progress. 
 
2.6 Cartilage and inflammatory markers associated with KOA 
 
KOA condition is associated with various cytokines which participate in affecting 
articular cartilage metabolism. IL-1β, TNF-α and IL-6 considered as the important pro-
inflammatory cytokines in pathophysiology of KOA. Highlight of these three cytokines 
can explained the network of pathogenesis of KOA. IL-1β is the essential pro-
inflammatory cytokine in the pathophysiology of KOA. It functions as suppressor of 
aggrecan and type II collagen found commonly at cartilage (Stove et al., 2000, 
Chadjichristos et al., 2003). IL-1β can induces production of inflammatory chemokines 
and cytokines such as IL-6 and IL-8 (Cahill and Rogers, 2008, Chen et al., 2005, Eskan et 
al., 2008). Since then, large scale of researches was working on IL-1β as future nominee 
biochemical marker. 
 TNF-α is another catabolic biomarker in KOA. TNF-α influenced the formation of 
cytokines such as IL-6 and IL-8 and is activated by macrophages (Aggarwal et al., 2013). 
TNF-α was first found as pro-inflammatory cytokine back in 1985 where it was known to 
stimulate PGE2 and collagenase from isolation of human dermal fibroblasts and synovial 
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cells (Dayer et al., 1985) . This proposed that TNF-α plays an important part in tissue 
destruction in inflammatory conditions. Both of IL-1β and TNF-α are recognized to induce 
lipid peroxidation and reactive oxygen species (ROS) which can lead to degradation of 
cartilage matrix (Tiku et al., 2000). IL-1β and TNF-α possessed an ability to stimulate 
production of nitric oxide (NO) which can inhibit proteoglycan synthesis and boost the 
production of MMP (Tyler, 1985, Dingle et al., 1979) .  
 IL-6 had been identified by several studies as pro-inflammatory cytokine in KOA 
pathophysiology. IL-6 level was reported high in subjects with radiographic KOA 
compared to control group (Livshits et al., 2009) and found increased in synovial 
inflammation in KOA (Martadiani et al., 2017). It is also capable to activate T-cell, B-cell 
and liase the engagement of other pro-inflammatory cells to inflammation area (Gabay, 
2006). 
 COMP is the member of the thrombospondin family which is a pentameric 
glycoprotein. It is synthesized by synovial cells and chondrocytes activated by 
proinflammatory cytokines (Zivanovic et al., 2011). COMP has a part in endochondral 
ossification, stabilization and accumulation of extracellular matrix through its relationship 
with matrix components and collagen fibrils (Recklies et al., 1998). Local inflammation 
of synovial joints caused the COMP to be released initially in the synovial fluid before it 
can be detected in blood and urine (Kawashiri et al., 2010). High COMP in blood reflects 
the catabolic events suggesting high turnover degree by the chondrocytes to compensate 
for the breakdown of cartilage matrix. COX-2 and PGE2 are two of the inflammatory 
biomarkers that essential in the inflammation event. Both play an important role in the 
sequential reactions in the AA pathway. COX-2 enzyme catalyzed the formation of 
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prostaglandin G2 (PGG2) in rate-limiting reaction and finally the production of PGE2 and 
the rest of PGs. High level of COX-2 level is accompanied by the induction of 
inflammatory cytokines. Reduction of COX-2 and PGE2 level believed to increase 
proteoglycan synthesis and cartilage damage (Mastbergen et al., 2002, Mastbergen et al., 
2005) in KOA cartilage. This made COMP (cartilage marker), COX-2 and PGE2 
(inflammatory markers) as the important cartilage and inflammatory biomarkers in the 
assessment of KOA disease.  
 
2.6.1 Cartilage Oligomeric Protein (COMP) 
COMP is a non-collagenous protein found abundantly in KOA cartilage. COMP 
was identified as a useful biomarker in distinguishing between normal and diseased 
individuals. It is also used to monitor the prognosis of KOA (Arellano et al., 2017, Kluzek 
et al., 2015, Georgiev et al., 2018, El-Arman et al., 2010). In the longest observational 
study by Kluzek et al., they observed and concluded their twenty years duration study with 
high serum COMP is associated with increased risk of developing radiographic KOA 
(Kluzek et al., 2015). This conclusion was similar with a study done by Blumenfeld et al. 
in 2013. However, other studies failed to find the relationship between serum COMP with 
radiographical grading (Verma and Dalal, 2013, Das Gupta et al., 2017). A study done by 
Gupta et al. on multi-ethnic Malaysian population with subjects varies from K-L grade 2 
to grade 4 showed gender is a factor of consideration in evaluating the level of serum and 
synovial fluid COMP (Das Gupta et al., 2017). Another study showed that higher level of 
serum COMP was reported in males (52%) compared to females (Verma and Dalal, 2013). 
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In Johnston County OA Project, a large-scale community study participated by 3187 
African American or Caucasian individuals age more than forty-five years old reported 
level of serum COMP of Caucasian men were higher than Caucasian women (Jordan et 
al., 2003). Singh et al. showed the male subjects had slightly higher level of serum COMP, 
but it is not statistically significant.  
 Positive finding regarding association of serum COMP and OA were demonstrated 
in animal studies. Animal study in China showed an increase of serum COMP level in the 
OA animal group and COMP level increased as OA advance (Bai and Li, 2016). This 
provided the evident that serum COMP could be considered as a biomarker in detecting 
and monitoring amelioration of cartilage loss. Measurement of serum COMP and joint 
fluids COMP were utilized as a specimen to determine the level of COMP during cartilage 
self-repair. As OA progress, there will be constant breakdown and self-repair by the 
cartilage. An animal study indicated that COMP level decreases as cartilage in repairing 
process (Chu et al., 2015). High COMP level also detected in several diseases other than 
KOA. Systemic Lupus Erythematosus (SLE) is an autoimmune disease in which own 
antibodies attack the joints, mucous membranes, lungs and sometimes the heart. A study 
comparing the patients with SLE with arthritis and SLE without arthritis indicated the SLE 
with arthritis had a high level of COMP in serum compared to SLE without arthritis 
(Fawzy et al., 2011). Sakthiswary et al. and Liu et al. conducted the researches of COMP 
level on rheumatoid arthritis (RA). Both came to a strong conclusion that elevated serum 
COMP in the disease suggested that COMP is a suitable test candidate in RA diagnosis 
(Sakthiswary et al., 2017, Liu et al., 2016). The changes of COMP level can serve as early 




2.6.2 Cyclooxygenase-2 (COX-2) 
COX-2, a 72-kd protein, is the essential enzyme in AA cascade. In physiological 
condition, COX-2 is expressed at low level (Funk, 2001). It is bounded within inner layer 
at phospholipid bilayer of nuclear envelope and endoplasmic reticulum (ER) (Spencer et 
al., 1998, Morita et al., 1995). It is not constitutively expressed as COX-1 but it can be 
induced tremendously by number of cytokines such as TNF-α, IL-1 and inflammatory 
stimuli (Crofford et al., 1994). COX-2 was released from many different types of cells 
such as endothelial cells, fibroblasts synovial cells, macrophages and monocytes (Wu et 
al., 2013). The induction of COX-2 by pro-inflammatory cytokines further converted AA 
which originated from cell membrane to form prostaglandin H2 (PGH2) and subsequent 
reactions from various PG syntheses metabolized to form multiple types of PGs and 
thromboxanes (Vane, 1971).  
COX-2 gene coordinated through 5’ (transcriptional and 3’ [post-transcriptional]) 
upon activation by IL-1β signal (Faour et al., 2001). The availability of binding sites for 
transcriptional factors utterly increase the gene transcription directly after activated by 
external stimuli (Yamamoto et al., 1995). The COX-2 protein level in synovial fibroblast 
cultures echoed the COX-2 mRNA in a study by Faour et al. and confirmed the explicit 
chemistry between message translation and expression (Faour et al., 2001). Several studies 
reported induction of COX-2 expression in human synovial fibroblast influenced by 
lipopolysaccharide (LPS), IL-1β, macrophage inhibitory factor (MIF) and TNF-α 
(Crofford et al., 1994, Hulkower et al., 1994, Roshak et al., 1996, Sampey et al., 2001). 
Study in China reported OA and RA subjects had high COX-2 level in supra patellar bursa 
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fluid compared to control group (Yang et. al., 2016). mRNA levels of COX-2 in synovial 
cells were elevated in OA and RA patients however COX-2 mRNA level in OA was much 
higher compared to patients with RA (Fan et al., 2015). The increment of COX-2 and the 
subsequent increased of PGE2 level is believed to cause the deterioration of proteoglycan 
synthesis within OA chondrocytes in concentration dependent manner (Hardy et al., 
2002). COX-2 also promotes inflammatory cytokines causing an imbalance in 
homeostasis of cartilage proteoglycan synthesis and further worsen the OA condition (Lee 















2.6.3 Prostaglandin E2 (PGE2) 
PGE2 is a prostanoid and lipid mediator of inflammation and pain. It is not stored 
but immediately metabolized. PGE2 is part of proactive PGs which is involved in the 
enzymatic metabolism conversion of AA to PGG2 and later converted to PGH2. PGH2 is 
tightly regulated by PG synthases and formed five primary prostanoids: prostaglandin D2 
(PGD2), PGE2, prostaglandin I2 (PGI2), prostaglandin F2α (PGF2α) and thromboxane A2 
(TXA2) (Figure 2.2). 




























There are three types of PGE2 synthases: microsomal PGES-1 (mPGES-1), 
microsomal PGES-2 (mPGES-2) and cytosolic PGES (cPGES). All PGE2 synthases had 
their specific function to regulate formation of PGE2 concentration (Park et al., 2006). 
PGE2 is well reported with the involvement in multiple normal physiological function 
such as fertility, blood pressure, gastrointestinal integrity and immune response (Legler et 
al., 2010). In pathophysiological aspect, PGE2 is also known to be associated with 
inflammation, pain and cancer (Nakanishi and Rosenberg, 2013, Hsu et al., 2017). 
Cytokines such as IL-1, TNF-α, NO synthase 2 (NOS2), MMP-1 and MMP-3 are some of 
the inflammatory cytokines and catabolic factors that downregulate the expression and 
synthesized by PGE2 (Blanco et al., 1995, Haas et al., 1990, Takayama et al., 1990, 
Fushimi et al., 2007, Noguchi et al., 2005). Avascular joint cartilages were due to the 
effects of PGE2 which are by autocrine and paracrine fashion (Guilak et al., 2004). These 
effects were dose-dependent (Funk, 2001, Harris et al., 2002, Sugimoto and Narumiya, 
2007).  
 
2.7 Treatment for KOA 
 
Basic treatment of KOA can divided into four categories: Non-pharmacologic, 
pharmacologic, complementary and alternative and lastly surgical (Sinusas, 2012). The 
fundamental understanding for KOA treatment is to begin with non-invasive type. 
Physical exercise is the commonest non-pharmacologic treatment of KOA patients. 
However, it is recommended for patients suffering with mild OA (Castrogiovanni et al., 
2016). Aquatic exercise is relatively a new regime of exercise to treat knee and hip OA 
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(Rewald et al., 2016, Bressel et al., 2014, Guerreiro et al., 2014). However, it has short-
term and small effects on OA patients.  
 By far, NSAIDs therapy are the first line treatment. NSAIDs are more effective to 
reduce the inflammation and swelling caused by OA (da Costa et al., 2017, Geba et al., 
2002) . Recently, intra articular injection become a popular therapy among OA patients. 
Experiments by intra articular on patients using platelet rich plasma (PRP), mesenchymal 
stem cells or glucosamine/chondroitin combination provided strong evidence that intra 
articular injection is a good option with low side effects to reduce pain and disability 
(Hammad et al., 2015; Campbell et al., 2015; Jo et al., 2017). However, intra articular 
injection of PRP only provided symptomatic relief up to 12 months (Campbell et al., 2015) 
. Complementary medicine like acupuncture is widely used and believed to improves the 
effect of medical treatment. Manheimer et al. and Manyanga et al. drew a conclusion and 
agreed that acupuncture is an effective therapy in reducing pain, enhance flexibility and 
quality of life (Manheimer et al., 2010, Manyanga et al., 2014) . Nonetheless, United 
Kingdom National Institute for Health and Care Excellence (NICE) was against the 
practice of acupuncture on KOA because lack of secured evidence related to the practice 
(Birch et al., 2017) .  
Glucosamine (2-amino-2-deoxy-D-glucose) (GlcN) and chondroitin 
supplementation are another popular remedy consumed as part of treatment for KOA 
patients worldwide. GlcN is a monosaccharide derivative of glucose. It is found 
consolidated into glucosaminoglycans, collagen and proteoglycan (Bassleer et. al., 1998). 
These are the essential components of articular cartilage. Proteoglycans are formed from 
glycosaminoglycan chain which is produced by glucosamine. Proteoglycans complexes 
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can create the pressure within cartilage, attract water and cope with mechanical loading 
(Huskisson, 2008). The proteoglycans are constantly undergoing breakdown and 
resynthesis with subjected to regular metabolic turnover. Hexosamine pathway is part of 
glycolytic pathway (Figure 2.3). Glucosamine directly entered the cells into glucose 
transport system and phosphorylated to glucosamine-6-phosphate (GlcN-6-P). N-acetyl-
glucosamine (GlcNAc) is formed before the pathway reach the end-product, uridine 
diphosphate N-acetyl-glucosamine (UDP-GlcNAc). GlcNAc retains a spectrum of anti-
inflammatory activities and inhibit IL-6, NO and COX-2 production in vitro (Shikhman 
et al., 2001). An in vitro study trying to elucidate the mechanism lied behind the 
effectiveness of GS in OA. They discovered that GS capable of reducing PLA2 and 
collagenase activity. GS acted on decreasing the cellular activity of PLA2 and directly 
slow down the AA pathway (Piperno et al., 2000). Reduction of enzyme PLA2 might cause 
the reduced synthesis of AA or n-3 fatty acids (which is substrate for COX-2) and 
indirectly reduced the COX-2 activity. This study confirmed the rational of consuming 
GS as part of KOA treatment in context of reducing COX-2 levels. However, many studies 
reported both the supplementations had side effects such as abdominal pain, heartburn, 
diarrhea, epigastric pain, nausea and flatulence are the known side effects of these 
supplementations (Tapadinhas et al., 1982, Huskisson, 2008). Even some studies reported 
administration of GlcN can induce mild dysfunction in β-cell secretion and exaggerate 
asthmatic condition (Monauni et al., 2000, Tallia and Cardone, 2002). A multicenter, 
randomized, double-blind, placebo-controlled study in Spain disclosed that there were no 
different found in Western Ontario and McMaster University Osteoarthritis Index 
(WOMAC), score and visual analog scale (VAS) between the intervention group and 
placebo (Roman-Blas et al., 2016). The same result was obtained by Rindone et al. in his 
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study to determine the capability of GlcN in reducing pain on ninety-eight KOA patients 
(Rindone et al., 2000).  
 
 
Interventions such as diet with nutrition, occupational related KOA and 
physiotherapy can be helpful in offering pain relief to KOA patients. Obese and 
overweight KOA patients were recommended to enforce a weight-loss plan which include 
suitable exercise regime to cater to their mobility ability. Supplements such as long-chain 
n-3 fatty acids may reduce pain and improve functions or controlled diet and integrating 
rich intake of vitamin K may aid to slow down OA progression (Thomas et al., 2018). 
 
 
Figure 2.3: Hexosamine Pathway 
Glc-6P, Glucose-6-phosphate; Glc-1P,Glucose-1-phosphate; UDP-Glc, Uridine Diphosphate glucose; Fru-6P, 
Fructose-6 phosphate; GFA, glutamine:fructose-6-P amidotransferase; GlcN-6-P, Glucosamine-6-phosphate; 
GlcN-1-P, Glucosamine-1-phosphate; GlcNA, N-Acetyl-glucosamine; UDP-GlcNAc, Uridine Diphosphate 
N-Acetyl- glucosamine; FFA, Free Fatty Acids (Adapted from (Hawkins et al., 1997))         
 
 
 
 
 
